Lexicon announces pricing of underwritten public offering of common stock

NewsGuard 100/100 Score

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement.

The offering will consist of 49,751,244 shares of common stock at a public offering price of $1.005 per share. Lexicon has also granted the underwriters a 30-day option to purchase up to 7,462,687 additional shares of common stock.

All of the shares in the offering will be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. are acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights impact of government vaccine recommendations and direct-to-consumer pharmaceutical advertising